# A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Source: https://onco.cc/trials/nct06362369/  
OnCo record `nct06362369` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ipilimumab, Nivolumab in metastatic cancer and melanoma, run by 7 Hills Pharma, LLC, now recruiting.

## Summary

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy is a phase 1/2 interventional study registered as NCT06362369 by 7 Hills Pharma, LLC, with 126 participants planned, started 2024-08-23 and due to reach its primary completion in 2027-12-31. Interventions recorded: Alintegimod, Ipilimumab, Nivolumab. Conditions listed: Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06362369
- Phase: 1/2
- Setting: A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies
- Sponsor: 7 Hills Pharma, LLC
- Enrolled: 126

## Sources

- ClinicalTrials.gov NCT06362369: https://clinicaltrials.gov/study/NCT06362369

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06362369.json